Vimarsana
Biggest News Aggregation in the World

Respir Rev News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Respir Rev. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Respir Rev Today - Breaking & Trending Today

Study: Anxiety May Increase Acute Exacerbation Risk for Older Patients With COPD - Vimarsana News

Study: Anxiety May Increase Acute Exacerbation Risk for Older Patients With COPD

Older patients with chronic obstructive pulmonary disease (COPD) and anxiety exhibited exacerbated symptoms, increased comorbidities, and frequent acute exacerbations of COPD (AECOPD), emphasizing the need for routine psychiatric screening in COPD management.

Source: ajmc.com
Severe asthma — breaking the cycle of inadequate care - Vimarsana News

Severe asthma — breaking the cycle of inadequate care

The real cost of severe asthma: Why urgent action is needed to protect patients and reduce the strain on stretched health systems.

The European Medicines Agency: A Modern Robin Hood? - Vimarsana News

The European Medicines Agency: A Modern Robin Hood?

Many studies with a stated goal of advancing child health care in administratively-defined minors have no clinical value and may even harm young patients.

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures - Vimarsana News

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative... | April 30, 2023

Pliant Therapeutics Announces Positive Long-Term Data from - Vimarsana News

Pliant Therapeutics Announces Positive Long-Term Data from

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care...